Abstract PD11-08: PD11-08 Trastuzumab Deruxtecan (T-Dxd) + Durvalumab (D) As First-Line (1L) Treatment for Unresectable Locally Advanced/metastatic Hormone Receptor-Negative (HR−), HER2-low Breast Cancer: Updated Results from BEGONIA, a Phase 1b/2 Study
Cancer Research（2023）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined